This study found that compounded topical minoxidil was associated with higher adherence, fewer side effects, and more clinical improvement in Black women compared to over-the-counter minoxidil.
This study found that while the over-the-counter market for minoxidil hair loss products is expanding, only 25% of these products report safety information, and none report adverse effects, highlighting a need for greater transparency and accuracy in their advertising.
1 citations
,
October 2024 in “Journal of Cosmetic Dermatology” This study conducted on YouTube Shorts videos found that a majority of content related to alopecia recommended treatments that could be carried out independently, such as over-the-counter medications, while professional recommendations by dermatologists comprised less than 15% of the videos but showed high viewer engagement.
September 2024 in “Journal of Cosmetic Dermatology” This study found that the topical application of DA-OTC-002, a combination of synephrine and tyramine hydrochloride, significantly reduced immediate hair shedding in women by 62.5% compared to a placebo, without any observed adverse effects.
September 2024 in “Journal of the American Academy of Dermatology” In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.